alias:: Dementia Praecox (historical term)  
ICD-11_Code:: 6A20  
tags:: disease, medicine, psychiatry  
high-yield:: true

- ## **Etiology**  
  background-color:: blue
	- ### **Causative Agents**
		- **Genetic factors** (polygenic inheritance, high heritability)
		- **Neurodevelopmental abnormalities** (prenatal infections, hypoxia)
		- **Neurochemical dysregulation** (dopamine, glutamate, serotonin hypotheses)
	- ### **Risk Factors**
		- Family history of schizophrenia
		- Advanced paternal age
		- Childhood trauma or adversity
		- Cannabis use (especially in adolescence)
		- Urban upbringing
		- Migration and social isolation
- ## **Epidemiology**  
  background-color:: blue
	- ### **Incidence**
		- ~15 new cases per 100,000 per year
	- ### **Prevalence**
		- ~0.3–0.7% lifetime prevalence globally
		- ### **Demographics**
			- Onset typically in late adolescence/early adulthood (males: 18–25, females: 25–35)
			- Slightly more common in males (1.4:1 ratio)
	- ### **Geographic Distribution**
		- Worldwide, with slight variations in incidence
- ## **Pathophysiology**  
  background-color:: blue
	- ### **Mechanism of Disease**
		- **Dopamine hypothesis** (hyperactivity in mesolimbic pathway → positive symptoms; hypoactivity in mesocortical pathway → negative/cognitive symptoms)
		- **Glutamate dysfunction** (NMDA receptor hypofunction)
		- **Neuroanatomical changes** (enlarged ventricles, reduced gray matter in prefrontal/temporal lobes)
	- ### **Affected Systems/Organs**
		- **Central nervous system** (cortical thinning, synaptic pruning abnormalities)
		- **Neuroendocrine system** (HPA axis dysregulation)
- ## **Clinical Features**  
  background-color:: blue
	- ### **Clinical Presentation**
		- #### **Symptoms**
			- **Positive symptoms**: Hallucinations (auditory most common), delusions, disorganized speech/behavior
			- **Negative symptoms**: Avolition, alogia, anhedonia, blunted affect
			- **Cognitive symptoms**: Impaired working memory, attention deficits
		- #### **Signs**
			- Disorganized thought process (tangentiality, loose associations)
			- Catatonia (rare)
	- ### **Stages or Classification**
		- >Shizophenon
		  *If the duration is less than 6 months (<6 months)*
		- **Prodromal phase** (social withdrawal, odd beliefs)
		- **Acute phase** (psychotic episode)
		- **Residual phase** (chronic symptoms, functional decline)
	- ### **Diagnostic Criteria**
		- **DSM-5**: ≥2 symptoms (delusions, hallucinations, disorganized speech, grossly disorganized behavior, negative symptoms) for ≥6 months with functional impairment
- ## **Diagnosis**  
  background-color:: blue
	- ### **Diagnostic Criteria**
		- #### **Clinical Diagnosis**
			- Persistent hallucinations + delusions with functional decline ;for 6 months
		- #### **Probable Diagnosis**
			- Rule out substance-induced psychosis, mood disorders with psychotic features
	- ### **Laboratory Tests**
		- No definitive test; rule out medical causes (CBC, metabolic panel, toxicology, TSH, B12, syphilis/HIV testing)
	- ### **Imaging Studies**
		- MRI (non-specific: enlarged ventricles, reduced hippocampal volume)
	- ### **Differential Diagnosis**
		- Bipolar disorder with psychotic features
		- Schizoaffective disorder
		- Delusional disorder
		- Substance-induced psychosis
	- ### **Confirmation of Diagnosis**
		- Clinical evaluation + exclusion of other causes
- ## **Management and Treatment**  
  background-color:: blue
	- ### **Medical Treatment**
		- **Antipsychotics**:
			- 1st-gen (haloperidol) or 2nd-gen (risperidone, olanzapine, clozapine for treatment-resistant cases)
		- Adjunctive: Mood stabilizers, antidepressants (for comorbid depression)
	- ### **Surgical Options**
		- None (historical lobotomy is obsolete)
	- ### **Lifestyle and Dietary Recommendations**
		- Smoking cessation (high prevalence in schizophrenia)
		- Regular exercise to mitigate metabolic side effects of antipsychotics
	- ### **Follow-up**
		- Long-term antipsychotic therapy + psychosocial interventions
- ## **Prognosis**  
  background-color:: blue
	- ### **Expected Course**
		- #### **With Treatment**
			- Symptom control possible, but functional impairment often persists
		- #### **Without Treatment**
			- Chronic disability, increased mortality (suicide, cardiovascular disease)
			- ##### **Possible Complications**
				- Suicide (5–10% lifetime risk)
				- Substance abuse
			- ##### **Long-Term Effects**
				- Cognitive decline, social isolation
	- ### **Survival Rates**
		- Life expectancy reduced by 10–20 years (due to comorbidities)
	- ### **Quality of Life Considerations**
		- Supported employment, social skills training improve outcomes
- ## **Prevention**  
  background-color:: blue
	- ### **Health Education**
		- Early intervention programs for at-risk youth
	- ### **Community Approach**
		- Reducing stigma, improving access to care
	- ### **Screening Programs**
		- No universal screening, but monitoring high-risk groups
	- ### **Lifestyle Modifications**
		- Avoiding cannabis in adolescence
- ## **Patient Education and Support**  
  background-color:: blue
	- ### **Educational Resources**
		- NAMI (National Alliance on Mental Illness)
	- ### **Support Groups**
		- Peer-led groups for schizophrenia
	- ### **Counseling Options**
		- Cognitive behavioral therapy for psychosis (CBTp)
- ## **Recent Research and Developments**  
  background-color:: blue
	- ### **Ongoing Clinical Trials**
		- Glutamate modulators (e.g., NMDA receptor agonists)
	- ### **Recent Advances**
		- Digital phenotyping for early detection
- ## **Key Literature**  
  background-color:: blue
	- *The Dopamine Hypothesis of Schizophrenia* (Howes et al., 2017)
- ## **Guidelines and Protocols**  
  background-color:: blue
	- APA (American Psychiatric Association) guidelines for schizophrenia treatment